Sign In  |  Register  |  About Los Altos  |  Contact Us

Los Altos, CA
September 01, 2020 1:26pm
7-Day Forecast | Traffic

  • Search Hotels in Los Altos

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

(NY: MAIA )

2.180 -0.040 (-1.80%)
Official Closing Price Updated: 8:00 PM EST, Nov 27, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about MAIA

< Previous 1 2 3 4 5 Next >
MAIA Biotechnology to Present at Biotech Showcase 2024 on January 9, 2024
From MAIA Biotechnology, Inc.
Via Business Wire
MAIA Biotechnology Announces Dose Selection in THIO-101 Phase 2 Clinical Trial for Non-Small Cell Lung Cancer
From MAIA Biotechnology, Inc.
Via Business Wire
MAIA Biotechnology Announces Closing of $4 Million Registered Direct Offering
From MAIA Biotechnology, Inc.
Via Business Wire
MAIA Biotechnology (NYSE: MAIA) Has Received FDA Orphan Drug Designation For THIO As A Treatment For Most Aggressive Brain Cancer
Via ACCESSWIRE
MAIA Biotechnology Reports Positive Phase 2 Clinical Trial Data On Its Treatment For Non-Small Cell Lung Cancer
Via ACCESSWIRE
What's Going On With Crispr Therapeutics Stock Thursday?
CRISPR Therapeutics AG (NASDAQ: CRSP) shares are trading higher Thursday after the company announced regulatory authorization of the first CRISPR/Cas9 gene- 
Via Benzinga
MAIA Biotechnology (NYSE: MAIA) Has Received FDA Orphan Drug Designation For THIO As A Treatment For Most Aggressive Brain Cancer
More than 300,000 people are diagnosed with brain cancer across the globe each year. 
Via Benzinga
Exposures Product Safety
Why MAIA Biotechnology Stock Is Nosediving During Wednesday's Session
MAIA Biotechnology Inc (NASDAQ: MAIA) shares are trading lower by 20.97% to $1.47 Wednesday morning after the company announced it's finalizing a deal to sell about 2.4 million shares of its common... 
Via Benzinga
MAIA Biotechnology Announces $4 Million Registered Direct Offering
From MAIA Biotechnology, Inc.
Via Business Wire
FDA Grants Orphan Drug Designation to MAIA Biotechnology for THIO as a Treatment for Glioblastoma
From MAIA Biotechnology, Inc.
Via Business Wire
MAIA Biotechnology Reports Third Quarter 2023 Financial Results and Highlights Recent Development Progress for Anticancer Asset THIO
From MAIA Biotechnology, Inc.
Via Business Wire
MAIA Biotechnology Reveals Higher Anticancer Potency of Telomere-Targeting Compounds Derived from THIO
From MAIA Biotechnology, Inc.
Via Business Wire
MAIA Biotechnology Reports Positive Phase 2 Clinical Trial Data On Its Treatment For Non-Small Cell Lung Cancer
New results from a targeted therapy and immuno-oncology company show the promising potential efficacy of one of its first-in-class treatments.  
Via Benzinga
MAIA Biotechnology Announces 100% Disease Control in Second-Line Non-Small Cell Lung Cancer Demonstrating Impressive Positive Preliminary Efficacy Data for Ongoing THIO-101 Phase 2 Trial
From MAIA Biotechnology, Inc.
Via Business Wire
MAIA Biotechnology to Present Preliminary Safety and Efficacy Data from THIO-101 Phase 2 Clinical Trial at European Society for Medical Oncology Congress 2023
From MAIA Biotechnology, Inc.
Via Business Wire
MAIA Biotechnology's THIO Emerges As Potential Breakthrough In Pediatric Brain Cancer Therapy
Via ACCESSWIRE
MAIA Biotechnology to Present Latest Findings for Second Generation THIO Program at Turkish Biochemical Society’s International Biochemistry Congress 2023
From MAIA Biotechnology, Inc.
Via Business Wire
MAIA Biotechnology's THIO Emerges As Potential Breakthrough In Pediatric Brain Cancer Therapy
Diffuse Intrinsic Pontine Glioma (DIPG) is among the most aggressive brain tumors affecting the central nervous system in children. 
Via Benzinga
MAIA Biotechnology Reveals New Data Showing THIO’s Potent Anticancer Activity in Aggressive Pediatric Brain Cancer
From MAIA Biotechnology, Inc.
Via Business Wire
MAIA Biotechnology Accelerates Enrollment in THIO-101 Phase II Clinical Trial as Efficacy Is Observed in Dosed Patients
From MAIA Biotechnology, Inc.
Via Business Wire
MAIA Biotechnology Announces Potent Anticancer Activity of THIO in Gliomas
From MAIA Biotechnology, Inc.
Via Business Wire
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
MAIA Secures FDA Clearance Of IND Application For THIO For Non-Small Cell Lung Cancer
MAIA Biotechnology, Inc. (AMEX: MAIA) announced that the U.S. 
Via Benzinga
Exposures Product Safety
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
MAIA Biotechnology Announces FDA Clearance of IND Application for THIO, a First-in-Class Telomere Targeting Agent for the Treatment of Non-Small Cell Lung Cancer
From MAIA Biotechnology, Inc.
Via Business Wire
MAIA Biotechnology Announces Share Repurchase Program
From MAIA Biotechnology, Inc.
Via Business Wire
MAIA Biotechnology Reports Second Quarter 2023 Financial Results and Provides Updates for THIO-101 Phase 2 Trial for Non-Small Cell Lung Cancer
From MAIA Biotechnology, Inc.
Via Business Wire
MAIA Biotechnology Reports Updates on Disease Control Rates for THIO-101 Phase 2 Trial for Advanced Non-Small Cell Lung Cancer
From MAIA Biotechnology, Inc.
Via Business Wire
MAIA Biotechnology Reports Updates on Preliminary Survival Data for THIO-101 Phase 2 Trial for Advanced Non-Small Cell Lung Cancer
From MAIA Biotechnology, Inc.
Via Business Wire
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
< Previous 1 2 3 4 5 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 LosAltos.com & California Media Partners, LLC. All rights reserved.